Sugi Predict

Sugi Predict / Compounds / SCHEMBL29360266

SCHEMBL29360266

SCHEMBL29360266

NCC(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 1/20 0.43
▸ GSTK1 Q9Y2Q3 1/20 0.43
▸ GLO1 Q04760 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ PTGS2 P35354 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ NMT1 P30419 5/20 0.35
▸ NMT2 O60551 4/20 0.35
▸ QRFPR Q96P65 2/20 0.35
▸ ECE1 P42892 1/20 0.33
▸ TERT O14746 1/20 0.33
▸ PTPN1 P18031 1/20 0.33
▸ MME P08473 1/20 0.33
▸ ACE P12821 1/20 0.33
▸ CPA1 P15085 1/20 0.33
▸ ACE2 Q9BYF1 1/20 0.33
▸ TGFBR1 P36897 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30642418 1.00 PTGS1 (0.43) PTGS1GSTK1GLO1ALDH1A1LMNA
SCHEMBL29356041 1.00 PTGS1 (0.43) PTGS1GSTK1GLO1ALDH1A1LMNA
SCHEMBL29437188 1.00 PTGS1 (0.43) PTGS1GSTK1GLO1ALDH1A1LMNA
SCHEMBL31018946 0.98 PTGS1 (0.43) PTGS1GSTK1GLO1ALDH1A1LMNA
SCHEMBL29509632 0.98 PTGS1 (0.43) PTGS1GSTK1GLO1ALDH1A1LMNA
SCHEMBL29375029 0.98 PTGS1 (0.43) PTGS1GSTK1GLO1ALDH1A1LMNA
SCHEMBL30662067 0.98 PTGS1 (0.43) PTGS1GSTK1GLO1ALDH1A1LMNA
SCHEMBL29906343 0.97 PTGS1 (0.42) PTGS1GSTK1GLO1ALDH1A1LMNA
SCHEMBL29607558 0.97 PTGS1 (0.42) PTGS1GSTK1GLO1ALDH1A1LMNA
SCHEMBL1862133 0.95 PTGS1 (0.43) PTGS1GSTK1GLO1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026107236-A1 COMPOSITIONS AND METHODS FOR VACCINATION AGAINST MYCOBACTERIUM TUBERCULOSIS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2026-05-21 — — WO disclosed
US-12570733-B2 Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules NOVARTIS AG (CH) 2026-03-10 — — US disclosed
EP-4608512-A2 ANTI-CD3 ANTIBODIES Ablexis, LLC (US) 2025-09-03 — — EP disclosed
CN-115074302-B Recombinant genetically engineered bacterium for producing (-) -alpha-bisabolol and preparation method and application thereof 上海锐康生物技术研发有限公司 2025-04-04 — — CN disclosed
EP-4489855-A1 ANTI-GLP1R ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF Regeneron Pharmaceuticals, Inc. (US) 2025-01-15 — — EP disclosed
EP-4376869-A1 IL15/IL15R ALPHA HETERODIMERIC FC-FUSION PROTEINS FOR THE TREATMENT OF BLOOD CANCERS Genentech, Inc. (US) 2024-06-05 — — EP disclosed
WO-2024092038-A2 ANTI-CD3 ANTIBODIES ABLEXIS, LLC (US) 2024-05-02 — — WO disclosed
US-20240124614-A1 ANTIGEN-BINDING MOLECULES WITH IMPROVED CYTOSOL-PENETRATING ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-04-18 — — US disclosed
US-20240043475-A1 PEPTIDE CONJUGATES Bioniz Therapeutics, Inc. 2024-02-08 — — US disclosed
EP-4267745-A1 ANTIGEN-BINDING MOLECULES WITH IMPROVED CYTOSOL-PENETRATING ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-01 — — EP disclosed
US-11462297-B2 Selective peptide antagonists BIONIZ, LLC (US) 2022-10-04 — — US disclosed
CN-115074302-A Recombinant gene engineering bacterium for producing (-) -alpha-bisabolol and preparation method and application thereof 上海锐康生物技术研发有限公司 2022-09-20 — — CN disclosed
CN-114702586-A anti-PDL 1 antibodies, activatable anti-PDL 1 antibodies, and methods of use thereof 西托姆克斯治疗公司 2022-07-05 — — CN disclosed
CN-114685661-A Matrix metalloprotease cleavable and serine protease cleavable substrates and methods of use thereof 西托姆克斯治疗公司 2022-07-01 — — CN disclosed
WO-2022138692-A1 ANTIGEN-BINDING MOLECULES WITH IMPROVED CYTOSOL-PENETRATING ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-06-30 — — WO disclosed
CN-114507283-A anti-CD 71 antibodies, activatable anti-CD 71 antibodies, and methods of use thereof 西托姆克斯治疗公司 2022-05-17 — — CN disclosed
CN-114478704-A Matrix metalloprotease cleavable and serine protease cleavable substrates and methods of use thereof 西托姆克斯治疗公司 2022-05-13 — — CN disclosed
CN-108026170-B anti-CD 71 antibodies, activatable anti-CD 71 antibodies, and methods of use thereof 西托姆克斯治疗公司 2022-03-01 — — CN disclosed
CN-108112254-B anti-PDL 1 antibodies, activatable anti-PDL 1 antibodies, and methods of use thereof 西托姆克斯治疗公司 2022-01-28 — — CN disclosed
US-20220025032-A1 ANTI-BETACELLULIN ANTIBODIES, FRAGMENTS THEREOF, AND MULTI-SPECIFIC BINDING MOLECULES NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570733-B2 Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules CRYAB, KDR, EDNRB PTGS1 1806/4885GSTK1 2410/4885GLO1 1648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.